关键词：急性痛风药物行业政策、急性痛风药物行业产业链、急性痛风药物市场规模、急性痛风药物市 场竞争格局、急性痛风药物重点企业介绍、急性痛风药物行业发展趋势 一、急性痛风药物行业定义及分类 内容概要：急性痛风是指痛风性关节炎急性发作。作为一种因嘌呤代谢紊乱和（或）尿酸排泄减少所引 发的疾病，急性痛风在全球范围内的发病率呈上升趋势，并呈年轻化发展趋势。18～35岁的年轻高尿酸 血症及痛风患者占比近60%，且男性比例显超女性。2024年，全球全球急性痛风患病人数增长至4540万 例，其中，中国急性痛风患病人数1940万例；预计2025年，全球全球急性痛风患病人数将增长至4770万 例，其中，中国急性痛风患病人数约2220万例。抗痛风急性发作期药物在缓解痛风急性发作症状方面发 挥着关键作用。虽近几年发病人数增加，但因价格上涨，销售量下降，近几年全球急性痛风药物市场规 模整体较稳定。预计2025年，全球急性痛风药物市场规模约为1.5美元，中国急性痛风药物市场规模约 0.1亿美元。 上市企业：海创药业[688302]、恒瑞医药[600276]、益方生物[688382]、一品红[300723] 相关企业：成都苑东生物制药股 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Core Viewpoint - The enthusiasm for insurance capital to acquire listed companies has surged, reaching 37 instances this year, marking a near 10-year high and the second highest in history, only behind 62 instances in 2015 [1][5]. Group 1: Regulatory Actions - The Hebei Securities Regulatory Bureau issued a warning letter to Great Wall Life Insurance for failing to disclose timely information regarding its acquisition of shares in Xintian Green Energy, violating the Securities Law of the People's Republic of China [3]. - Great Wall Life Insurance increased its stake in Xintian Green Energy to 5.0027% by acquiring 1 million shares, but did not halt trading upon reaching the 5% threshold, which is a regulatory requirement [3][4]. Group 2: Company Performance - Great Wall Life Insurance's insurance business revenue for the first three quarters of 2025 was 21.455 billion yuan, a decrease of 5.92% compared to 22.806 billion yuan in the same period last year [4]. - The net profit for Great Wall Life Insurance in the first three quarters of 2025 was 872 million yuan, down 70.92% from 2.972 billion yuan in the same period of 2024, with a quarterly net loss of 122 million yuan [4]. Group 3: Market Trends - The current year has seen a significant increase in insurance capital acquisitions, with a notable focus on high-quality equity investments, particularly in sectors like banking, public utilities, and environmental protection [7]. - The insurance capital's preference for high ROE and high dividend stocks indicates a strategic shift towards stable investment returns, with various insurance companies participating in the acquisition trend [7][8]. - The asset allocation of insurance funds in stocks and funds has risen to 15.5%, creating more room for acquisitions and signaling a positive outlook for the market [8].

Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Health Insurance Innovative Drug List has significantly benefited innovative drug companies on the Sci-Tech Innovation Board [1] - A total of 9 innovative drugs from Sci-Tech Innovation Board companies have been included in the new list, showcasing their strong capabilities [1] - The simultaneous release of the commercial insurance drug list marks a substantial breakthrough in the multi-layered payment system of "medical insurance + commercial insurance" [1] Group 1: Inclusion in Medical Insurance - Nearly 90% of innovative drugs from Sci-Tech Innovation Board companies have received medical insurance support, accelerating their value release and development [2] - Junshi Bioscience's drug, Junsida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance list [2] - Haichuang Pharmaceutical's drug, Hainaan, has been approved for treating metastatic castration-resistant prostate cancer and will enhance market promotion and patient accessibility [2] Group 2: New Drug Development - New anti-tumor drugs from companies like Ailis, Yifang Biotech, and Shenzhou Cell provide precise treatment options for major diseases such as lung cancer and head and neck squamous cell carcinoma [3] - Several drugs covering endocrine, hematology, tumor support, and autoimmune treatment areas have been quickly included in the medical insurance list, demonstrating efficient drug review and approval processes [3] Group 3: Commercial Health Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug List enhances the national multi-layered medical security system, with a clear division of roles between basic medical insurance and commercial insurance [4] - Innovative drugs from leading companies like BeiGene have been among the first to be included in this new directory, showcasing their clinical value [4][5] Group 4: Renewal and Market Expansion - Successful renewal negotiations confirm the exceptional value and clinical status of innovative drugs from Sci-Tech Innovation Board companies [6] - Junshi Bioscience's drug, Tuoyi, has expanded its medical insurance coverage with new indications, benefiting a broader patient population [6] Group 5: R&D Investment and Innovation Cycle - R&D investment among Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42% [7] - The formation of a virtuous cycle of "R&D investment - innovation results - medical/commercial insurance support - market returns - reinvestment in R&D" is evident in the industry [7]

海创药业涨超10%，前沿生物涨超8%，悦康药业、热景生物、回盛生物、众生药业跟涨。 (本文来自第一财经) 海创药业涨超10%，前沿生物涨超8%，悦康药业、热景生物、回盛生物、众生药业跟涨。 (本文来自第一财经) ...

Core Insights - On December 10, 2023, brokerage firms provided target prices for listed companies, with significant increases noted for Yilian Network, Xingfu Electronics, and Yingke Recycling, showing target price increases of 53.21%, 40.35%, and 35.77% respectively, across the communication equipment, electronic chemicals, and plastics industries [1][2]. Group 1: Target Price Increases - Yilian Network received a target price of 53.50 yuan, reflecting a target price increase of 53.21% [2]. - Xingfu Electronics was assigned a target price of 52.00 yuan, with a target price increase of 40.35% [2]. - Yingke Recycling's target price is set at 40.04 yuan, indicating a target price increase of 35.77% [2]. - Guizhou Tire, with a target price of 6.60 yuan, shows a target price increase of 29.92% [2]. - Guki Wool Material has a target price of 33.00 yuan, reflecting a target price increase of 23.32% [2]. Group 2: Rating Adjustments - Three companies had their ratings upgraded on December 10, including Yingke Recycling, which was upgraded from "Hold" to "Buy" by Huatai Securities [3][4]. - Tian Nai Technology's rating was raised from "Hold" to "Outperform" by Guosen Securities [3][4]. - Haiguang Information's rating was upgraded from "Range Trading" to "Buy" by Qunyi Securities (Hong Kong) [3][4]. Group 3: First-Time Coverage - Eight companies received initial coverage from brokerages on December 10, including Guizhou Tire, which was rated "Buy" by Global Fortune Financial [5][6]. - Fusheng Technology received an "Increase" rating from China Merchants Securities [5][6]. - Kaizhong Co. was rated "Increase" by Northeast Securities [5][6]. - Hand Information was rated "Buy" by CITIC Construction Investment Securities [5][6]. - Guki Wool Material was rated "Increase" by Tianfeng Securities [5][6].

【导读】上午三大指数涨跌不一， CPO持续走强，创新药、消费电子、零售股上涨；而贵金属、房地产等板块走弱 中国基金报记者 张舟 大家好，基金君和你继续关注今天的市场行情！ 12月9日上午，A股三大股指涨跌不一。截至午间收盘，沪指报3918.83点，跌0.13%，深证成指涨0.09%，创业板指涨1.07%。 沪深两市半日成交额为1.26万亿元，较上个交易日缩量347亿元。 个股涨多跌少，全市场共1738只个股上涨，40只个股涨停，有3555只 个股下跌。 从板块看，光模块（CPO）持续拉涨，创新药、消费电子、商业百货、培育钻石概念板块走强；而贵金属、房地产等板块领跌。 | | | Wind热门概念指数 | | | | | Wind中国行业指数 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 覆铜板 | 电路板 | | 电路交换机(光模块(CPO) | 培育钻石 | 电子元器件 | 办公用品 | 通信设备 | 零售 | 重型机械 | | 3.95% | 2.93% | 2.93% | 2.59% | 2.49% | 2.5 ...

板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | ...

每经AI快讯，海创药业（SH 688302，收盘价：47.51元）12月8日晚间发布公告称，公司第二届第十五 次董事会会议于2025年12月8日在公司会议室以通讯表决方式召开。会议审议了《关于修订 <公司章程> 的议案》等文件。 2025年1至6月份，海创药业的营业收入构成为：药品占比99.25%，材料及研发中间体占比0.75%。 （记者 曾健辉） 截至发稿，海创药业市值为47亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 ...

海创药业股份有限公司 章程 二零二五年十二月 | 第一章 | 总则 - | 1 - | | --- | --- | --- | | 第二章 | 经营宗旨和范围 - | 2 - | | 第三章 | 股份 - | 2 - | | 第一节 | 股份发行 | - 3 - | | 第二节 | 股份增减和回购 | - 6 - | | 第三节 | 股份转让 | - 7 - | | 第四章 | 股东和股东会 - | 8 - | | 第一节 | 股东的一般规定 | - 8 - | | 第二节 | 控股股东和实际控制人 - | 10 - | | 第三节 | 股东会的一般规定 - | 11 - | | 第四节 | 股东会的召集 - | 14 - | | 第五节 | 股东会的提案与通知 - | 16 - | | 第六节 | 股东会的召开 - | 17 - | | 第七节 | 股东会的表决和决议 - | 20 - | | 第五章 | 董事和董事会 - | 23 - | | 第一节 | 董事的一般规定 - | 24 - | | 第二节 | 董事会 - | 27 - | | 第三节 | 独立董事 - | 30 - | | 第四节 | 董事 ...